

SARS-CoV-2 Omicron virus causes attenuated disease in

Nature

603, 687-692

DOI: [10.1038/s41586-022-04441-6](https://doi.org/10.1038/s41586-022-04441-6)

Citation Report

#	ARTICLE	IF	CITATIONS
4	Omicron severity: milder but not mild. <i>Lancet</i> , The, 2022, 399, 412-413.	13.7	124
9	The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. <i>Antiviral Research</i> , 2022, 198, 105253.	4.1	104
10	Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. <i>Environmental Research</i> , 2022, 209, 112816.	7.5	189
12	A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method. <i>Viruses</i> , 2022, 14, 313.	3.3	10
13	Infection and pathogenesis of the Delta variant of SARS-CoV-2 in Rhesus macaque. <i>Virologica Sinica</i> , 2022, , .	3.0	4
16	Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 642-652.	3.8	161
19	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1987.	4.1	48
20	Critical View on the Importance of Host Defense Strategies on Virus Distribution of Bee Viruses: What Can We Learn from SARS-CoV-2 Variants?. <i>Viruses</i> , 2022, 14, 503.	3.3	1
21	Successive Pandemic Waves with Different Virulent Strains and the Effects of Vaccination for SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 343.	4.4	4
24	Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2408.	4.1	13
26	Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression. <i>Viruses</i> , 2022, 14, 535.	3.3	47
27	COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development. <i>Microorganisms</i> , 2022, 10, 598.	3.6	14
28	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11.	28.9	71
30	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
31	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. <i>Organoids</i> , 2022, 1, 2-27.	3.1	12
32	Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?. <i>Journal of Virology</i> , 2022, 96, jvi0207721.	3.4	143
33	Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. <i>Cell Reports</i> , 2022, 39, 110688.	6.4	14
35	Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective. <i>ChemBioChem</i> , 2022, 23, e202200059.	2.6	35

#	ARTICLE	IF	CITATIONS
36	A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 902-913.	6.5	7
37	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	28.9	179
38	Global trends in COVID-19. , 2022, 1, 31-39.		8
39	SARS-CoV-2 pathogenesis. <i>Nature Reviews Microbiology</i> , 2022, 20, 270-284.	28.6	404
41	Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. <i>Cell</i> , 2022, 185, 1539-1548.e5.	28.9	126
43	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 38, 110558.	6.4	15
44	The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. <i>Trends in Neurosciences</i> , 2022, 45, 358-368.	8.6	118
45	Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529). <i>Biology</i> , 2022, 11, 400.	2.8	10
46	Animal models in SARS-CoV-2 research. <i>Nature Methods</i> , 2022, 19, 392-394.	19.0	51
48	Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. <i>Med</i> , 2022, 3, 262-268.e4.	4.4	117
49	Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. <i>EBioMedicine</i> , 2022, 79, 103997.	6.1	29
51	Croup Associated With SARS-CoV-2: Pediatric Laryngotracheitis During the Omicron Surge. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 371-374.	1.3	16
52	Structures of Omicron spike complexes and implications for neutralizing antibody development. <i>Cell Reports</i> , 2022, 39, 110770.	6.4	47
55	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	3.3	10
56	Nasally delivered interferon- β protects mice against infection by SARS-CoV-2 variants including Omicron. <i>Cell Reports</i> , 2022, 39, 110799.	6.4	39
57	The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. <i>MBio</i> , 2022, 13, e0068322.	4.1	17
58	Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <i>Tropical Medicine and International Health</i> , 2022, 27, 564-573.	2.3	94
61	Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1406-1409.	0.8	26

#	ARTICLE	IF	CITATIONS
62	COVID-19 and tuberculosis: the double whammy of respiratory pathogens. <i>European Respiratory Review</i> , 2022, 31, 210264.	7.1	40
63	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. <i>Cell Reports</i> , 2022, 39, 110729.	6.4	102
64	COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2022, 15, 1927-1939.	4.2	41
65	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. <i>Inflammation</i> , 2022, 45, 1430-1449.	3.8	16
66	Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 967-976.	9.1	140
67	Protection of Hamsters Challenged with SARS-CoV-2 Delta Variant after Two Doses of Adjuvanted SARS-CoV-2 Stabilized Prefusion Spike Protein (S-2P) and a Single Dose of Beta Variant S-2P. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	5
68	The immune response to COVID-19: Does sex matter?. <i>Immunology</i> , 2022, 166, 429-443.	4.4	18
69	An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. <i>Science Translational Medicine</i> , 2022, 14, eabn7737.	12.4	34
70	Animal models for studying COVID-19, prevention, and therapy: Pathology and disease phenotypes. <i>Veterinary Pathology</i> , 2022, 59, 516-527.	1.7	5
71	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	4.6	24
72	Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 139.	17.1	14
73	Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1093-1102.e3.	11.0	114
75	SARS-CoV-2 Omicron variant: recent progress and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 141.	17.1	315
76	Shell Disorder Models Detect That Omicron Has Harder Shells with Attenuation but Is Not a Descendant of the Wuhan-Hu-1 SARS-CoV-2. <i>Biomolecules</i> , 2022, 12, 631.	4.0	4
77	Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. <i>Cell Reports</i> , 2022, 39, 110829.	6.4	214
78	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. <i>Biosafety and Health</i> , 2022, 4, 154-160.	2.7	3
79	Making a Joint Decision Regarding The Timing of Surgery For Elective Arthroplasty Surgery After Being Infected With COVID-19: A Systematic Review. <i>Journal of Arthroplasty</i> , 2022, , .	3.1	5
81	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. <i>Cell</i> , 2022, 185, 2103-2115.e19.	28.9	273

#	ARTICLE	IF	CITATIONS
82	The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Developmentâ€”A Systematic Review. <i>Viruses</i> , 2022, 14, 991.	3.3	10
83	Emerging SARS-CoV-2 variants: Why, how, and what's next?. , 2022, 1, 100029.		26
84	Advances in Modelling COVID-19 in Animals. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	2.8	0
85	Pathogenicity of SARSâ€CoVâ€2 Omicron. <i>Clinical and Translational Medicine</i> , 2022, 12, e880.	4.0	12
86	Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. <i>Viruses</i> , 2022, 14, 1020.	3.3	58
87	Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters. <i>EBioMedicine</i> , 2022, 80, 104035.	6.1	4
88	Many Keys Unlock the Doors for Virus Entry. <i>MBio</i> , 2022, , e0044522.	4.1	0
89	Integrin/TGF-Î²1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity. <i>Pharmaceuticals</i> , 2022, 15, 618.	3.8	12
90	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127.	27.8	174
91	Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. <i>Nature</i> , 2022, 607, 351-355.	27.8	143
94	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	9.0	54
95	Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease. <i>Emerging Infectious Diseases</i> , 2022, 28, .	4.3	11
96	Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021â€January 2022: A retrospective, population-based, matched cohort study. <i>EClinicalMedicine</i> , 2022, 48, 101455.	7.1	49
97	Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969.	6.3	120
99	An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. <i>Biology</i> , 2022, 11, 797.	2.8	10
100	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. <i>Nature Microbiology</i> , 2022, 7, 896-908.	13.3	32
101	Could a Lower Toll-like Receptor (TLR) and NF-Î²B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5966.	4.1	9
102	Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice. <i>Viruses</i> , 2022, 14, 1139.	3.3	21

#	ARTICLE	IF	CITATIONS
103	Recent insights into SARS-CoV-2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	8.3	29
104	Estimating relative generation times and reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta variant in Denmark. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 9005-9017.	1.9	32
105	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	13.6	35
106	Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies. <i>Viruses</i> , 2022, 14, 1334.	3.3	45
107	Boosting with variant-matched vaccines: an opportunity to win the race against Omicron. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	0
108	Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study). <i>Frontiers in Immunology</i> , 0, 13, .	4.8	26
109	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	3.2	24
110	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. <i>Nature Communications</i> , 2022, 13, .	12.8	73
111	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. <i>Science Immunology</i> , 2022, 7, .	11.9	89
113	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	12.6	113
114	The Ecology of Viral Emergence. <i>Annual Review of Virology</i> , 2022, 9, 173-192.	6.7	20
116	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. <i>Nature Microbiology</i> , 2022, 7, 1252-1258.	13.3	20
117	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	3.3	30
118	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	12.8	22
119	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	14
120	SARS-CoV-2, platelets, and endothelium: coexistence in space and time, or a pernicious ménage à trois?. <i>Vascular Biology (Bristol, England)</i> , 2022, 4, R35-R43.	3.2	5
121	SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
122	K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research. <i>Molecules</i> , 2022, 27, 4142.	3.8	7

#	ARTICLE	IF	CITATIONS
124	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	6.0	9
125	Sequencing during Times of Change: Evaluating SARS-CoV-2 Clinical Samples during the Transition from the Delta to Omicron Wave. <i>Viruses</i> , 2022, 14, 1408.	3.3	3
126	Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro. <i>Journal of Infectious Diseases</i> , 2023, 227, 202-205.	4.0	10
127	Considering innate immune responses in SARS-CoV-2 infection and COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 465-470.	22.7	14
128	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. <i>Microorganisms</i> , 2022, 10, 1450.	3.6	28
131	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	3.5	7
132	A booster dose of Delta-Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	7.0	42
133	Animal models for COVID-19: advances, gaps and perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	40
134	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	4.0	16
135	Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
136	Importance score of SARS-CoV-2 genome predicts the death risk of COVID-19. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	2
138	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. <i>Emerging Microbes and Infections</i> , 2022, 11, 1778-1786.	6.5	7
139	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	12.8	93
140	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	6.1	128
141	Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. <i>Nature Microbiology</i> , 2022, 7, 1376-1389.	13.3	33
142	Alveolar macrophages: Achilles' heel of SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	15
144	Global, regional, and national incidence and mortality of COVID-19 in 237 countries and territories, January 2022: a systematic analysis for World Health Organization COVID-19 Dashboard. , 0, 2, .		28
145	Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. <i>Cell Research</i> , 2022, 32, 831-842.	12.0	16

#	ARTICLE	IF	CITATIONS
146	SARS-CoV-2 S2â€‘targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	57
147	Evolution of ACE2-independent SARS-CoV-2 infection and mouse adaption after passage in cells expressing human and mouse ACE2. <i>Virus Evolution</i> , 2022, 8, .	4.9	14
149	Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. <i>Viruses</i> , 2022, 14, 1769.	3.3	1
150	A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .	3.4	15
151	Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease. <i>MBio</i> , 0, , .	4.1	3
152	COVID-19 Omicron variant-induced laryngitis. <i>Auris Nasus Larynx</i> , 2022, , .	1.2	7
153	Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. <i>Vaccine</i> , 2022, 40, 5892-5903.	3.8	6
154	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. <i>Journal of Virology</i> , 2022, 96, .	3.4	12
155	Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Emerging Microbes and Infections</i> , 2022, 11, 2315-2325.	6.5	3
156	Assessing the suitability of long non-coding RNAs as therapeutic targets and biomarkers in SARS-CoV-2 infection. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	6
158	Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	43
161	The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .	3.4	35
162	The Omicron (B.1.1.529) SARS-CoV-2 variant of concern also affects companion animals. <i>Frontiers in Veterinary Science</i> , 0, 9, .	2.2	20
163	The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children. <i>Frontiers in Pediatrics</i> , 0, 10, .	1.9	19
164	Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	6
165	Understanding COVID-19-associated coagulopathy. <i>Nature Reviews Immunology</i> , 2022, 22, 639-649.	22.7	137
166	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. <i>Nature Communications</i> , 2022, 13, .	12.8	12
167	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	12.8	23

#	ARTICLE	IF	CITATIONS
168	Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
169	A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .	3.4	5
170	Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
172	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. <i>EBioMedicine</i> , 2022, 83, 104196.	6.1	26
173	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	5.6	56
174	CLN7/MFSD8 may be an important factor for SARS-CoV-2 cell entry. <i>IScience</i> , 2022, 25, 105082.	4.1	1
175	SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. <i>EBioMedicine</i> , 2022, 84, 104270.	6.1	86
176	Wastewater to clinical case (WC) ratio of COVID-19 identifies insufficient clinical testing, onset of new variants of concern and population immunity in urban communities. <i>Science of the Total Environment</i> , 2022, 853, 158547.	8.0	19
177	Characterizing the third wave of COVID-19. <i>Indian Journal of Medical Research</i> , 2022, Publish Ahead of Print, .	1.0	1
178	Are atypical lymphocytes a new predictive factor in the development of COVID-19?. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 55, .	0.9	0
179	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
180	Covid-Associated Pernio is the Product of an Abortive Sars-Cov-2 Infection Resulting in the Deposition of Inflammatory Viral Rna and a Local Interferon Response. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
181	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. <i>Advances in Infectious Diseases</i> , 2022, 12, 568-631.	0.2	1
182	The Fc-Effector Function of COVID-19 Convalescent Plasma Contributes to SARS-CoV-2 Treatment Efficacy in Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
183	Experimental measurement of respiratory particles dispersed by wind instruments and analysis of the associated risk of infection transmission. <i>Journal of Aerosol Science</i> , 2023, 167, 106070.	3.8	2
184	A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	10
185	Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases. <i>Clinical Infectious Diseases</i> , 2023, 76, e18-e25.	5.8	15
187	Rhabdomyolysis in Pediatric Patients with SARS-CoV-2 Infection. <i>Children</i> , 2022, 9, 1441.	1.5	4

#	ARTICLE	IF	CITATIONS
188	B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	6
189	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
191	Does diabetes risk after SARS-CoV-2 infection depend on the viral variant?. <i>Diabetes Research and Clinical Practice</i> , 2022, 191, 110054.	2.8	3
192	Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743.	6.5	19
193	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	55
194	Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
195	COVID-19 Spotlights Connections between Disease and Multiple Lifestyle Factors. <i>American Journal of Lifestyle Medicine</i> , 0, , 155982762211230.	1.9	4
196	Characterization of <sc>SHARPIN</sc> knockout Syrian hamsters developed using <sc>CRISPR</sc>/Cas9 system. <i>Animal Models and Experimental Medicine</i> , 2023, 6, 489-498.	3.3	2
197	Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. <i>Emerging Microbes and Infections</i> , 2022, 11, 2275-2287.	6.5	48
198	Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. <i>Cell Reports</i> , 2022, 40, 111359.	6.4	23
199	An <sc>ACE2</sc> decoy can be administered by inhalation and potently targets omicron variants of <sc>SARS-CoV-2</sc>. <i>EMBO Molecular Medicine</i> , 2022, 14, .	6.9	28
200	Building a Resilient Scientific Network for COVID-19 and Beyond. <i>MBio</i> , 0, , .	4.1	1
201	In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	24
202	Scaling Biosafety Up During and Down After the COVID-19 Pandemic. <i>Applied Biosafety</i> , 2022, 27, 247-254.	0.5	1
203	Global "flu-ization" of COVID-19: A perspective from Vietnam. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	8
204	An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .	6.0	8
209	SARS-CoV-2 Omicron variant is attenuated for replication in a polarized human lung epithelial cell model. <i>Communications Biology</i> , 2022, 5, .	4.4	34
210	Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. , 2022, 19, 1392-1399.		5

#	ARTICLE	IF	CITATIONS
212	Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
213	Limited permissibility of ENL-R and Mv-1-Lu mink cell lines to SARS-CoV-2. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	0
214	The Burden of Omicron Variant in Pakistan: An Updated Review. <i>Covid</i> , 2022, 2, 1460-1476.	1.5	1
215	Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways. <i>Nature Communications</i> , 2022, 13, .	12.8	46
216	Characteristics of animal models for COVID-19. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 401-409.	3.3	7
217	Choosing a cellular model to study SARS-CoV-2. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	22
218	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. <i>Nature Medicine</i> , 2023, 29, 247-257.	30.7	98
219	Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	19
220	Comparison of SARS-CoV-2 Viral Loads in the Nasal Mucosa of Patients Infected With BA.1, BA.2, or BA.5 Omicron Lineages. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
221	SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice. <i>Emerging Infectious Diseases</i> , 2022, 28, 2352-2355.	4.3	0
222	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. <i>Nature</i> , 2022, 612, 540-545.	27.8	60
223	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	39
224	Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. <i>IScience</i> , 2022, 25, 105479.	4.1	24
225	Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model. <i>IScience</i> , 2022, 25, 105475.	4.1	8
226	Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	2.7	9
227	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	12.8	11
228	SARS-CoV-2 variants: Impact on biological and clinical outcome. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	7
229	A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3

#	ARTICLE	IF	CITATIONS
230	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	4.1	10
232	Assessment, diagnosis and treatment of children who present with stridor. <i>Emergency Nurse</i> , 2023, 31, 27-32.	0.2	0
233	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. <i>International Immunopharmacology</i> , 2022, 113, 109428.	3.8	22
234	SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. <i>Science Advances</i> , 2022, 8, .	10.3	28
235	Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
236	Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. <i>Journal of Infection and Public Health</i> , 2023, 16, 4-14.	4.1	105
237	Stimulation of interferon- β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists. <i>IScience</i> , 2023, 26, 105742.	4.1	4
241	Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. <i>Viruses</i> , 2022, 14, 2584.	3.3	6
242	Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
243	Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and Omicron variant strain in Quanzhou: A real-world study. <i>Experimental and Therapeutic Medicine</i> , 2022, 25, .	1.8	9
246	Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	7
248	Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa. <i>Clinical Infectious Diseases</i> , 2023, 76, 1468-1475.	5.8	15
249	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	12.8	17
250	Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1010970.	4.7	13
251	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. <i>Cell Reports</i> , 2022, 41, 111845.	6.4	46
252	Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
254	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	3.0	12
255	Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations. <i>Pathogens</i> , 2023, 12, 20.	2.8	4

#	ARTICLE	IF	CITATIONS
257	A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. <i>Cell Discovery</i> , 2022, 8, .	6.7	12
258	Fatal cases after Omicron BA.1 and BA.2 infection: Results of an autopsy study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 51-57.	3.3	2
259	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. <i>Journal of Virology</i> , 0, , .	3.4	4
260	Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. <i>MBio</i> , 2023, 14, .	4.1	14
261	A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. <i>Viruses</i> , 2023, 15, 167.	3.3	87
263	Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150.	27.8	52
268	A Selective SARS-CoV-2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species. <i>ACS Central Science</i> , 0, , .	11.3	1
270	Analysis of SARS-CoV-2 Cases, COVID-19 Outcomes and Vaccinations, during the Different SARS-CoV-2 Variants in Greece. <i>Vaccines</i> , 2023, 11, 126.	4.4	2
271	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. <i>Journal of Virology</i> , 0, , .	3.4	2
272	SARS-CoV-2 variants induce distinct disease and impact in the bone marrow and thymus of mice. <i>IScience</i> , 2023, 26, 105972.	4.1	3
273	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	28.6	160
274	Effect of nasal irrigation in adults infected with Omicron variant of COVID-19: A quasi-experimental study. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	3
275	Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. <i>Nature Neuroscience</i> , 2023, 26, 226-238.	14.8	14
276	The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. <i>Cell Reports Medicine</i> , 2023, 4, 100893.	6.5	16
277	Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract. <i>Trends in Food Science and Technology</i> , 2023, 132, 40-53.	15.1	12
279	A C57BL/6 Mouse Model of SARS-CoV-2 Infection Recapitulates Age- and Sex-Based Differences in Human COVID-19 Disease and Recovery. <i>Vaccines</i> , 2023, 11, 47.	4.4	6
280	The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. <i>Viruses</i> , 2023, 15, 95.	3.3	8
281	Animal models and SARS-CoV-2-induced pulmonary and neurological injuries. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	1.6	0

#	ARTICLE	IF	CITATIONS
282	Altered host protease determinants for SARS-CoV-2 Omicron. <i>Science Advances</i> , 2023, 9, .	10.3	12
283	Transcriptomic approaches in COVID-19: From infection to vaccines. , 2023, , 125-144.		0
284	SARS-CoV-2 and its impact on the cardiovascular and digestive systems – The interplay between new virus variants and human cells. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1022-1029.	4.1	2
286	SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. <i>Diagnostics</i> , 2023, 13, 559.	2.6	12
287	Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An In Silico Investigation. <i>Antibodies</i> , 2023, 12, 17.	2.5	6
288	SARS-CoV-2 Exposure in Norway Rats (<i>Rattus norvegicus</i>) from New York City. <i>MBio</i> , 2023, 14, .	4.1	12
289	Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant. <i>PLoS Pathogens</i> , 2023, 19, e1011293.	4.7	7
290	Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models. <i>Antiviral Research</i> , 2023, , 105605.	4.1	0
291	In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. <i>EBioMedicine</i> , 2023, 91, 104561.	6.1	14
292	A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	20
294	Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model. <i>IScience</i> , 2023, 26, 106092.	4.1	5
295	Development of a novel mathematical model that explains SARS-CoV-2 infection dynamics in Caco-2 cells. <i>PeerJ</i> , 0, 11, e14828.	2.0	2
296	Chronological changes of viral shedding in adult inpatients with Omicron infection in Shanghai, China. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
297	Angiotensin-converting enzyme 2 at the heart of the COVID-19 pandemic. <i>Cell</i> , 2023, 186, 906-922.	28.9	36
298	Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. <i>PLoS Biology</i> , 2023, 21, e3001989.	5.6	6
299	Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. <i>Lancet, The</i> , 2023, 401, 664-672.	13.7	84
301	Animal Models, Zoonotic Reservoirs, and Cross-Species Transmission of Emerging Human-Infecting Coronaviruses. <i>Annual Review of Animal Biosciences</i> , 2023, 11, 1-31.	7.4	8
302	Origin and evolution of SARS-CoV-2. <i>European Physical Journal Plus</i> , 2023, 138, .	2.6	16

#	ARTICLE	IF	CITATIONS
303	Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study. <i>BMJ Open Respiratory Research</i> , 2023, 10, e001274.	3.0	1
304	SARS-CoV-2 S Glycoprotein Stabilization Strategies. <i>Viruses</i> , 2023, 15, 558.	3.3	1
305	Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study. <i>Viruses</i> , 2023, 15, 597.	3.3	7
306	Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. <i>PLoS Pathogens</i> , 2023, 19, e1011168.	4.7	8
307	BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. <i>PLoS Pathogens</i> , 2023, 19, e1011196.	4.7	6
308	COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses. <i>EBioMedicine</i> , 2023, 89, 104485.	6.1	4
309	SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. <i>Viruses</i> , 2023, 15, 639.	3.3	1
310	SARS-CoV-2 related bat virus behavior in human-relevant models sheds light on the origin of COVID-19. <i>EMBO Reports</i> , 2023, 24, .	4.5	4
311	Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 516-525.	3.1	3
312	In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5120.	4.1	2
313	A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
314	Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6037144 coronavirus disease 2019-positive patients. <i>Clinical Microbiology and Infection</i> , 2023, 29, 835-844.	6.0	29
315	SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model. <i>Antiviral Research</i> , 2023, 212, 105580.	4.1	2
316	Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses. <i>EMBO Molecular Medicine</i> , 2023, 15, .	6.9	8
317	Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. <i>Nature Communications</i> , 2023, 14, .	12.8	11
318	Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2. <i>Npj Vaccines</i> , 2023, 8, .	6.0	1
319	Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study. <i>Infection</i> , 2023, 51, 1093-1102.	4.7	3
320	Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice. <i>Npj Vaccines</i> , 2023, 8, .	6.0	1

#	ARTICLE	IF	CITATIONS
321	Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level. <i>EBioMedicine</i> , 2023, 90, 104545.	6.1	17
322	SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100537.	3.8	2
324	Fc- γ 3R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. <i>Nature Microbiology</i> , 2023, 8, 569-580.	13.3	33
325	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. <i>MBio</i> , 2023, 14, .	4.1	9
326	Murine Coronavirus Disease 2019 Lethality Is Characterized by Lymphoid Depletion Associated with Suppressed Antigen-Presenting Cell Functionality. <i>American Journal of Pathology</i> , 2023, 193, 866-882.	3.8	2
327	Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. <i>PLoS Pathogens</i> , 2023, 19, e1011206.	4.7	8
328	SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters. <i>MBio</i> , 0, , .	4.1	4
329	Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study. <i>Nature Communications</i> , 2023, 14, .	12.8	8
330	<i>In silico</i> analysis of ACE2 from different animal species provides new insights into SARS-CoV-2 species spillover. <i>Future Virology</i> , 2023, 18, 359-371.	1.8	1
331	Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021. <i>Infection, Genetics and Evolution</i> , 2023, 111, 105434.	2.3	1
332	Understanding COVID-19-related myocarditis: pathophysiology, diagnosis, and treatment strategies. <i>Cardiology Plus</i> , 0, Publish Ahead of Print, .	0.7	1
333	Associations between SARS-CoV-2 infection and incidence of new chronic condition diagnoses: a systematic review. <i>Emerging Microbes and Infections</i> , 2023, 12, .	6.5	3
335	Mice Humanized for MHC and hACE2 with High Permissiveness to SARS-CoV-2 Omicron Replication. <i>Microbes and Infection</i> , 2023, , 105142.	1.9	0
336	Virulence Profiles of Wild-Type, P.1 and Delta SARS-CoV-2 Variants in K18-hACE2 Transgenic Mice. <i>Viruses</i> , 2023, 15, 999.	3.3	3
337	Trends in Severe Outcomes Among Adult and Pediatric Patients Hospitalized With COVID-19 in the Canadian Nosocomial Infection Surveillance Program, March 2020 to May 2022. <i>JAMA Network Open</i> , 2023, 6, e239050.	5.9	8
338	Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. <i>PLoS Pathogens</i> , 2023, 19, e1010870.	4.7	11
339	Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6. <i>Nature Communications</i> , 2023, 14, .	12.8	15
340	Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. <i>Nature Communications</i> , 2023, 14, .	12.8	116

#	ARTICLE	IF	CITATIONS
341	Omicron variant evolution on vaccines and monoclonal antibodies. <i>Inflammopharmacology</i> , 2023, 31, 1779-1788.	3.9	9
345	A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. <i>Communications Biology</i> , 2023, 6, .	4.4	2
346	Accelerating antiviral drug discovery: lessons from COVID-19. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 585-603.	46.4	25
347	A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8. <i>Nature Communications</i> , 2023, 14, .	12.8	5
348	Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	4
349	Host and viral determinants of airborne transmission of SARS-CoV-2 in the Syrian hamster. <i>ELife</i> , 0, 12, .	6.0	0
351	Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity. <i>Heliyon</i> , 2023, 9, e16750.	3.2	1
352	Role of Therapeutic Anticoagulation in COVID-19: The Current Situation. <i>Hematology Reports</i> , 2023, 15, 358-369.	0.8	4
353	SARS-CoV-2 Omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	2
354	De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 0, , .	4.0	0
355	A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants. <i>IScience</i> , 2023, 26, 107085.	4.1	3
356	VSV- \hat{P} G-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants. <i>Viruses</i> , 2023, 15, 1364.	3.3	0
357	Altered hACE2 binding affinity and S1/S2 cleavage efficiency of SARS-CoV-2 spike protein mutants affect viral cell entry. <i>Virologica Sinica</i> , 2023, 38, 595-605.	3.0	1
358	Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants. <i>Viruses</i> , 2023, 15, 1398.	3.3	1
359	OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
360	Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. <i>EBioMedicine</i> , 2023, 93, 104677.	6.1	5
361	Immunological imprinting of humoral immunity to SARS-CoV-2 in children. <i>Nature Communications</i> , 2023, 14, .	12.8	6
362	Infection with Seasonal H1N1 Influenza Results in Comparable Disease Kinetics and Host Immune Responses in Ferrets and Golden Syrian Hamsters. <i>Pathogens</i> , 2023, 12, 668.	2.8	2

#	ARTICLE	IF	CITATIONS
364	SARS-CoV-2 Omicron variant causes brain infection with lymphoid depletion in a mouse COVID-19 model. <i>Laboratory Animal Research</i> , 2023, 39, .	2.5	5
365	Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies. <i>Pathogens</i> , 2023, 12, 713.	2.8	4
366	Antiviral activity of basidial fungus <i>Inonotus obliquus</i> ; aqueous extract against SARS-CoV-2 virus (Coronaviridae: Betacoronavirus: Sarbecovirus) in vivo in BALB/c mice model. <i>Voprosy Virusologii</i> , 2023, 68, 152-160.	0.7	0
367	SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
370	The NSP4 T492I mutation increases SARS-CoV-2 infectivity by altering non-structural protein cleavage. <i>Cell Host and Microbe</i> , 2023, 31, 1170-1184.e7.	11.0	7
373	An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo. <i>Nature Communications</i> , 2023, 14, .	12.8	5
374	Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	1
375	IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation. <i>Nature Communications</i> , 2023, 14, .	12.8	8
376	Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein. <i>Nature Structural and Molecular Biology</i> , 2023, 30, 980-990.	8.2	9
377	ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	5
378	In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. <i>Nature Communications</i> , 2023, 14, .	12.8	15
379	Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters. <i>Nature Communications</i> , 2023, 14, .	12.8	6
380	Differential Characteristics of Patients for Hospitalized Severe COVID-19 Infected by the Omicron Variants and Wild Type of SARS-CoV-2 in China. <i>Journal of Inflammation Research</i> , 0, Volume 16, 3063-3078.	3.5	3
381	Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants. <i>International Journal of Biological Macromolecules</i> , 2023, 249, 125997.	7.5	0
382	Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants. <i>Nature Communications</i> , 2023, 14, .	12.8	15
384	SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models. <i>Journal of Virology</i> , 2023, 97, .	3.4	7
385	Efficacy, Pharmacokinetics, and Toxicity Profiles of a Broad Anti-SARS-CoV-2 Neutralizing Antibody. <i>Viruses</i> , 2023, 15, 1733.	3.3	0
386	Transchromosomal bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants. <i>IScience</i> , 2023, 26, 107764.	4.1	2

#	ARTICLE	IF	CITATIONS
387	Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review. <i>Vaccines</i> , 2023, 11, 1502.	4.4	3
388	Animal models to study the neurological manifestations of the post-COVID-19 condition. <i>Lab Animal</i> , 2023, 52, 202-210.	0.4	2
389	Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants. <i>Journal of Virology</i> , 2023, 97, .	3.4	1
390	Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters. <i>Journal of Virology</i> , 2023, 97, .	3.4	2
391	SARS-CoV-2 nonstructural protein 6 from Alpha to Omicron: evolution of a transmembrane protein. <i>MBio</i> , 0, , .	4.1	1
392	Initial immune response after exposure to <i>Mycobacterium tuberculosis</i> or to SARS-COV-2: similarities and differences. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
393	Multi-omics analysis of attenuated variant reveals potential evaluation marker of host damaging for SARS-CoV-2 variants. <i>Science China Life Sciences</i> , 0, , .	4.9	0
394	SuPAR mediates viral response proteinuria by rapidly changing podocyte function. <i>Nature Communications</i> , 2023, 14, .	12.8	1
396	Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice. <i>Communications Biology</i> , 2023, 6, .	4.4	2
397	The Influence of the Omicron Variant on RNA Extraction and RT-qPCR Detection of SARS-CoV-2 in a Laboratory in Brazil. <i>Viruses</i> , 2023, 15, 1690.	3.3	0
398	Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	1
399	Association of SARS-CoV-2 viral load with abnormal laboratory characteristics and clinical outcomes in hospitalised COVID-19 patients. <i>Epidemiology and Infection</i> , 2023, 151, .	2.1	0
400	Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development. <i>Journal of Infectious Diseases</i> , 2023, 228, S337-S354.	4.0	0
401	Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines. <i>Npj Vaccines</i> , 2023, 8, .	6.0	0
402	Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants. <i>Nature Communications</i> , 2023, 14, .	12.8	8
403	A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages. <i>Advanced Science</i> , 2023, 10, .	11.2	3
404	The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. <i>EBioMedicine</i> , 2023, 95, 104753.	6.1	8
405	Upper Respiratory Tract OC43 Infection Model for Investigating Airway Immune-modifying Therapies. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 0, , .	2.9	0

#	ARTICLE	IF	CITATIONS
410	Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	1
411	Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. <i>Science Advances</i> , 2023, 9, .	10.3	6
412	Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5. <i>Science Advances</i> , 2023, 9, .	10.3	4
414	Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tract. <i>Med</i> , 2023, , .	4.4	0
417	Humoral and cellular immunity against diverse SARS-CoV-2 variants. <i>Journal of Genetics and Genomics</i> , 2023, 50, 934-947.	3.9	1
418	Transgenic mouse models support a protective role of type I IFN response in SARS-CoV-2 infection-related lung immunopathology and neuroinvasion. <i>Cell Reports</i> , 2023, 42, 113275.	6.4	0
419	An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models. <i>Nature Communications</i> , 2023, 14, .	12.8	2
420	Omicron breakthrough infections in vaccinated or previously infected hamsters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	1
421	Phenotyping the virulence of SARS-CoV-2 variants in hamsters by digital pathology and machine learning. <i>PLoS Pathogens</i> , 2023, 19, e1011589.	4.7	3
422	From Emergence to Endemicity: A Comprehensive Review of COVID-19. <i>Cureus</i> , 2023, , .	0.5	1
423	Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection. <i>Vaccines</i> , 2023, 11, 1732.	4.4	0
424	Use of a point-of-care test to rapidly assess levels of SARS-CoV-2 nasal neutralising antibodies in vaccinees and breakthrough infected individuals. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
425	Low level of tonic interferon signalling is associated with enhanced susceptibility to SARS-CoV-2 variants of concern in human lung organoids. <i>Emerging Microbes and Infections</i> , 2023, 12, .	6.5	1
426	Utility of Bronchoalveolar Lavage for the Diagnosis and Management of COVID-19 in Patients With Cancer. <i>Journal of Infectious Diseases</i> , 2023, 228, 1549-1558.	4.0	0
427	Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies. <i>Journal of Immunology</i> , 2023, 211, 1459-1467.	0.8	2
428	Evolution of SARS-CoV-2 Spikes shapes their binding affinities to animal ACE2 orthologs. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	0
429	One Health and Engineering: using engineering to further pave the roadmap towards global health security, pandemic preparedness, and personalized medicine. <i>DYNA (Colombia)</i> , 2023, 90, 22-28.	0.4	0
430	SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	1

#	ARTICLE	IF	CITATIONS
431	Cleavage-Activation of Respiratory Viruses – Half a Century of History from Sendai Virus to SARS-CoV-2. <i>Japanese Journal of Infectious Diseases</i> , 2024, 77, 1-6.	1.2	0
432	Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases. <i>Journal of Chemotherapy</i> , 0, , 1-6.	1.5	0
433	Lack of detection of SARS-CoV-2 in British wildlife 2020–21 and first description of a stoat (<i>Mustela</i>) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.9	1
434	Virological Characteristics of Five SARS-CoV-2 Variants, Including Beta, Delta and Omicron BA.1, BA.2, BA.5. <i>Viruses</i> , 2023, 15, 2394.	3.3	0
435	Growth hormone–releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	0
436	Inactivated whole virion vaccine protects K18–hACE2 Tg mice against the Omicron SARS–CoV–2 variant via cross–reactive T cells and nonneutralizing antibody responses. <i>European Journal of Immunology</i> , 0, , .	2.9	0
437	Prevalência de Influenza A, vírus sincicial respiratório e SARS-COV-2 em pacientes com síndrome respiratória aguda grave em Passo Fundo - RS. <i>Semina: Ciências Biológicas E Da Saúde</i> , 2023, 44, 113-126.	0.2	0
438	Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. <i>Cell Reports</i> , 2023, 42, 113580.	6.4	4
439	Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract. <i>EBioMedicine</i> , 2024, 99, 104916.	6.1	1
440	Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models. <i>Advanced Science</i> , 2024, 11, .	11.2	2
441	Changing character and waning impact of COVID-19 at a tertiary centre in Cape Town, South Africa. <i>Southern African Journal of Infectious Diseases</i> , 2023, 38, .	0.5	0
442	Efficacy and safety of glucocorticoids use in patients with COVID-19: a systematic review and network meta-analysis. <i>BMC Infectious Diseases</i> , 2023, 23, .	2.9	0
444	Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	1
445	Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice. <i>Viruses</i> , 2024, 16, 60.	3.3	0
446	Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model. <i>EBioMedicine</i> , 2024, 99, 104950.	6.1	0
447	Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity. <i>MBio</i> , 2024, 15, .	4.1	1
448	SARS-CoV-2 immunity in animal models. , 2024, 21, 119-133.		1
449	The Abundant Distribution and Duplication of SARS-CoV-2 in the Cerebrum and Lungs Promote a High Mortality Rate in Transgenic hACE2-C57 Mice. <i>International Journal of Molecular Sciences</i> , 2024, 25, 997.	4.1	1

#	ARTICLE	IF	CITATIONS
450	SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. <i>Cell</i> , 2024, 187, 596-608.e17.	28.9	9
451	Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives. <i>Radiology</i> , 2024, 310, .	7.3	0
452	Augmentation of Omicron BA.1 pathogenicity in hamsters using intratracheal inoculation. , 2024, 2, .		0
453	ACE2 and TMPRSS2 distribution in the respiratory tract of different animal species and its correlation with SARS-CoV-2 tissue tropism. <i>Microbiology Spectrum</i> , 2024, 12, .	3.0	0
454	Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. <i>Nature Communications</i> , 2024, 15, .	12.8	1
455	An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.. <i>Antiviral Research</i> , 2024, 222, 105815.	4.1	0
456	Divergent pathogenetic outcomes in BALB/c mice following Omicron subvariant infection. <i>Virus Research</i> , 2024, 341, 199319.	2.2	0
457	Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
458	Causes and Consequences of Coronavirus Spike Protein Variability. <i>Viruses</i> , 2024, 16, 177.	3.3	0
459	Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue. <i>Nature Communications</i> , 2024, 15, .	12.8	0
460	Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens. <i>IScience</i> , 2024, 27, 109049.	4.1	0
461	Lack of detection of SARS-CoV-2 in wildlife from Kerala, India in 2020â€“21. <i>Access Microbiology</i> , 2024, 6, .	0.5	0
462	Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters. <i>Journal of Virology</i> , 2024, 98, .	3.4	0
463	Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. <i>Nature Immunology</i> , 2024, 25, 537-551.	14.5	0
464	Identification of SARS-CoV-2 in urban rodents from Southern Mexico City at the beginning of the COVID-19 pandemic. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 0, 66, .	1.1	0
465	A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity. <i>Nature Communications</i> , 2024, 15, .	12.8	0
466	Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19. <i>Virulence</i> , 2024, 15, .	4.4	0
467	A Novel Rat Model to Simulate the Benign Esophageal Stricture Induced by Endoscopic Submucosal Dissection. <i>Clinical and Experimental Gastroenterology</i> , 0, Volume 17, 41-50.	2.3	0

#	ARTICLE	IF	CITATIONS
469	Host and viral determinants of airborne transmission of SARS-CoV-2 in the Syrian hamster. <i>ELife</i> , 0, 12, .	6.0	0
470	The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection. <i>Journal of Virology</i> , 2024, 98, .	3.4	0
471	Comparison of Computed Tomography and Clinical Features Between Patients Infected with the SARS-CoV-2 Omicron Variant and the Original Strain. <i>Infection and Drug Resistance</i> , 0, Volume 17, 807-818.	2.7	0
473	Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	17.1	0
474	Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. <i>Communications Biology</i> , 2024, 7, .	4.4	0
475	Socioeconomic inequalities in healthcare system efficiency in Japan during COVID-19 pandemic: an analysis of the moderating role of vaccination. <i>Frontiers in Public Health</i> , 0, 12, .	2.7	0